BioSpace News Archive

TÜV SÜD America Inc., a global leader in testing, inspection / audit and certification, announces a new collaboration with Applied DNA Sciences (ADNAS) to offer their scientific traceability services as a complement to TÜV SÜD’s product traceability solution.

High exposure to per- and polyfluoroalkyl substances (PFAS) during pregnancy may be associated with lower birthweights, according to a new study funded by Environmental influences on Child Health Outcomes Program (ECHO) at the National Institutes of Health.

Sofwave Medical Ltd announced receipt of U.S. Food and Drug Administration clearance of the Company’s 510 notification submission for its “Precise” compact SUPERB™ applicator to improve facial lines and wrinkles, lift the eyebrow, and lift lax submental and neck tissue; which can also affect the appearance of lax tissue in the submental and neck regions.

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma,

Trethera Corporation (“Trethera”) received a unanimous recommendation from the independent safety review committee (“SRC”) to continue clinical trial advancement of Trethera’s lead development asset, TRE-515, its first-in-class deoxycytidine kinase (“dCK”) inhibitor.

UCB, a global biopharmaceutical company, and Aitia, the leader in the application of Causal AI and “Digital Twins” to discover and develop new drugs, today announced an early drug discovery collaboration focused on the discovery and validation of novel drug targets and drug candidates for Huntington’s disease.

OncoResponse today announced a poster presentation at the upcoming American Association for Cancer Research Annual Meeting being held April 14-19, 2023, at the Orange County Convention Center in Orlando, Florida.

Matinas BioPharma, a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal platform delivery technology, reports 2022 financial results and provides a business update.

Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”) today announced that it will release its fourth quarter and full year 2022 financial results after market close on Wednesday, March 22, 2023.

Taysha Gene Therapies, Inc. announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2022, and host a corporate update conference call and webcast on Tuesday, March 28, 2023, at 4:30 PM Eastern Time.